Researched company map
14 assessed companies
Every mapped company is assessed with evidence-qualified exposure. Materiality is claimed only where disclosure supports it.
Mobility and orthopaedic devices, including hip and knee reconstruction, trauma and enabling technology.Q1 2026 Orthopaedics net sales were $2.813 billion. Knees were $670 million, hips were $460 million, and the SEC filing attributed underlying constant-currency growth across Orthopaedics businesses to increased unit volume after excluding acquisitions and divestitures (src-stryker-q1-2026-sec).
- Evidence
- The SEC filing directly supports segment and product-category figures. It does not attribute revenue to aging in place or quantify older-adult demand; that linkage is analytical and remains NOT_READY.
- Materiality
- disclosed — Orthopaedics is a disclosed segment representing $2.813 billion of $6.020 billion Q1 2026 net sales; aging-in-place attribution is not disclosed.
- Investability view
- Official evidence supports a material orthopaedic business, but demographic attribution, product-level economics, competitive advantage and valuation remain NOT_READY.
Next diligence: Quantify Mako adoption and implant pull-through from official evidence; separate unit volume, price, acquisitions, divestitures and currency; complete licensed valuation and independent human review.
Orthopaedic reconstruction and enabling technology, including hip and knee implants.Q1 2026 net sales were $2.0867 billion, including $828.6 million from knees and $524.1 million from hips. The SEC filing says knees and hips benefited from customer purchases, market growth and new-product introductions (src-zbh-q1-2026-sec).
- Evidence
- The SEC Form 10-Q replaces the prior secondary summary and directly supports the reported figures. It does not quantify older-adult or aging-in-place revenue.
- Materiality
- disclosed — Knees and hips together represented $1.3527 billion of $2.0867 billion Q1 2026 net sales; demographic attribution is not disclosed.
- Investability view
- Official evidence supports material knee and hip exposure, but organic durability, ROSA economics, competitive advantage and valuation remain NOT_READY.
Next diligence: Separate organic performance from Paragon 28, currency and timing; quantify ROSA adoption and procedure-volume trends; complete licensed valuation and independent human review.
Hearing instruments, audiology retail and cochlear implants that can support communication and independence.Sonova reports CHF 3,605.9 million of FY2025/26 sales and states that hearing-care demand is expected to expand with aging populations and longer treatment horizons (src-sonova-fy2026-financial; src-sonova-fy2026-strategy).
- Evidence
- Official annual-report evidence replaces the prior market-research summaries. The report directly supports demographic relevance and company scale, but not the removed market-share estimate or an aging-attributable revenue percentage.
- Materiality
- disclosed — Sonova's reported operations are concentrated in hearing instruments and cochlear implants, and its annual report explicitly identifies aging populations as a demand driver.
- Investability view
- Official evidence supports direct hearing-care exposure and an issuer-stated aging-demand link, but product-cycle durability, channel economics and valuation remain NOT_READY.
Next diligence: Review hearing-instrument wholesale and retail economics, product-cycle durability, cochlear-implant recovery, currency sensitivity and licensed valuation; obtain independent human acceptance.
Hearing aids, hearing-care distribution and diagnostic instruments and services.Q1 2026 group revenue was DKK 6,246 million with 6% organic growth. External Hearing Aids revenue was DKK 2,535 million with 9% organic growth, and Hearing Care revenue was DKK 3,123 million with 4% organic growth (src-demant-q1-2026).
- Evidence
- Official issuer reports replace the prior market-research summaries. The sources directly support hearing-healthcare exposure and reported performance, but not the removed market-share estimate or an aging-attributable revenue percentage.
- Materiality
- disclosed — Demant's disclosed business areas are Hearing Aids, Hearing Care and Diagnostics; aging-in-place attribution is not separately disclosed.
- Investability view
- Official evidence supports material hearing-healthcare exposure, but demographic attribution, product-cycle durability, channel economics and valuation remain NOT_READY.
Next diligence: Separate organic growth from KIND acquisition and currency effects; review Oticon Zeal durability, retail and diagnostics economics, restructuring delivery and licensed valuation; obtain independent human acceptance.
Transitional hearing-care exposure through the Hearing division, including ReSound, while the announced divestment remains pending.GN reported Q1 2026 Hearing revenue of DKK 1,755 million, 9% organic growth and adjusted EBITA of DKK 300 million, but classified Hearing as discontinued operations following the divestment announcement. The continuing business is Enterprise and Gaming (src-gn-q1-2026).
- Evidence
- Official Q1 2026 reporting directly supports the current financial contribution and discontinued-operations classification. It does not support durable post-closing Aging in Place exposure for GN.
- Materiality
- estimated — The current Hearing economics are disclosed, but future theme materiality is blocked by the pending divestment and cannot be inferred from pre-transaction results.
- Investability view
- NOT_READY: the relationship may cease to be valid after the Hearing divestment closes.
Next diligence: Track the divestment through closing, define any retained economics and reassess this relationship from GN's first post-closing report.
Home respiratory devices, recurring masks and supplies, and software used across home medical equipment and residential-care workflows.Q3 FY2026 Sleep and Breathing Health revenue was $1,260.5 million and Residential Care Software revenue was $170.9 million. Filing commentary identifies Home and Hospice, Home Medical Equipment, Senior Living and Long-Term Care software verticals (src-resmed-q3-fy2026-sec).
- Evidence
- The SEC filing directly supports product, segment and current-period financial claims. It does not quantify revenue from older adults or the Aging in Place theme.
- Materiality
- estimated — Home and residential-care products are disclosed and financially material; aging-specific attribution remains unreported and requires human review.
- Investability view
- Current filing evidence supports home and residential-care operations, but theme attribution and valuation remain NOT_READY.
Next diligence: Quantify resupply economics, reimbursement sensitivity and an acceptable age or at-home-care attribution; obtain licensed valuation and human review.
Continuous glucose monitoring that can support chronic-disease management outside clinical settings.DexCom reported Q1 2026 revenue of $1,191.9 million. Its CONNECT trial reported improved glucose-control outcomes in adults with Type 2 diabetes not using insulin regardless of age (src-dexcom-q1-2026-sec; src-dexcom-connect-2026). Neither source quantifies older-adult revenue or establishes the previously predicted Medicare coverage expansion.
- Evidence
- The SEC filing supports current financial results; the issuer trial release supports the reported study population and outcomes. Policy expansion and aging-specific materiality remain unsupported and are excluded.
- Materiality
- estimated — CGM is relevant to independent chronic-disease management, but DexCom does not disclose age-segmented or Aging in Place revenue.
- Investability view
- Current filing and trial evidence support CGM operations and adult clinical utility, but reimbursement expansion, theme attribution and valuation remain NOT_READY.
Next diligence: Review the peer-reviewed CONNECT publication and any official coverage decision; quantify payer and age exposure only from acceptable primary evidence.
Continuous glucose monitoring within Abbott's diversified Medical Devices portfolio.Abbott reported Q2 2026 Diabetes Care sales of $2,188 million within $5,853 million of Medical Devices sales and $12,593 million of total company sales. Continuous glucose monitor sales grew 11.0% reported (src-abbott-q2-2026). These data do not establish an older-adult or Aging in Place share.
- Evidence
- Abbott's official Q2 2026 release directly supports the current segment and franchise figures. It does not support the prior predicted Medicare expansion or theme-wide company materiality.
- Materiality
- estimated — Diabetes Care is a disclosed, measurable franchise within a diversified company; aging-specific attribution is not disclosed.
- Investability view
- Current issuer evidence supports a relevant monitoring franchise, but consolidated theme attribution and valuation remain NOT_READY.
Next diligence: Review official payer and age-mix disclosures; separate CGM economics from Abbott's broader portfolio; obtain licensed valuation and human review.
Home-based care services - personal care, home health and hospice; the most direct 'care in place' operator among mapped names.Q1 2026 revenue $363.6M (+7.7%); personal care $281.1M = 77.3% of revenue (+8.8%, +6.5% same-store); hospice $65.8M (+7.1%); home health $16.7M (src-addus). Almost the entire business is delivered in the home, tying it directly to the theme - and to Medicaid reimbursement and caregiver supply.
- Evidence
- Segment detail obtained via a reputable secondary summary of Addus's Q1 2026 release; the Medicaid-heavy personal-care mix links revenue to state HCBS rates (KFF, src-kff) and to caregiver availability (PHI, src-phi). Confirm figures against the 10-Q.
- Materiality
- disclosed — Segment revenues are disclosed (via a secondary summary of the company release) and the business is overwhelmingly in-home; theme materiality is high and disclosed pending primary confirmation.
- Investability view
- Direct in-home care operator with solid volume growth, but the most exposed mapped name to the reimbursement thesis-break (Medicaid ~$911B risk) and caregiver labor scarcity.
Next diligence: Confirm figures vs 10-Q; Medicaid rate exposure by state; labor cost/turnover; acquisition pipeline and integration.
Post-acute inpatient rehabilitation (facility-based); enables older patients to recover function and return to independent living.As the largest US inpatient rehabilitation operator, Encompass serves an aging post-acute population, but care is delivered in facilities rather than in the home - a thematically indirect fit that supports returning home rather than delivering care in place. No company-specific current financials were retrieved this session (IR pages did not return figures).
- Evidence
- IR/newsroom pages did not yield fetched financials this session; the thematic linkage is inferred from the company's known role and the aging post-acute demand base, not from fetched company data.
- Materiality
- not assessed — No company-specific evidence was fetched this session, and the facility-based model is an indirect fit to 'aging in place'; materiality cannot be responsibly assigned without primary data.
- Investability view
- Demographic tailwind to rehab demand is real, but the in-place linkage is indirect; evaluate separately from home-based names and confirm reimbursement outlook.
Next diligence: Pull recent 2026 results (discharge growth, revenue, hospital count); size any home-health/hospice arm; Medicare IRF (inpatient rehab facility) rate outlook.
Home and alternate-site infusion therapy - delivery of infused medications outside the hospital, including in the home.Option Care is a pure-play provider of infusion care delivered in the home and at alternate sites, a model that is definitionally 'care in place' for chronic and acute conditions common among older adults. No current-period company financials were retrieved this session (the IR endpoint errored), so the exposure rests on business-model alignment rather than fetched data.
- Evidence
- No company-specific financials or segment mix were fetched this session; strong structural alignment is asserted from the known business model, not from fetched evidence.
- Materiality
- not assessed — Business-model alignment is strong, but no company-specific evidence was fetched this session; per an evidence-first standard, materiality is left not_assessed pending primary data.
- Investability view
- Structurally aligned in-home care model that fits the theme well; assess payer mix, drug-margin dynamics and referral trends before forming conviction.
Next diligence: Pull the latest 10-Q (revenue, gross profit, chronic vs acute infusion mix); payer concentration; drug-pricing/reimbursement exposure; nursing-labor availability.
Home-modification enabler (second-order) - installer of insulation and related building products.IBP's revenue is primarily tied to new-residential and commercial construction (insulation), with limited and unquantified linkage to age-related accessibility retrofits. JCHS confirms aging drives remodeling broadly (44% of 25M+ 65+ households need accessibility features; src-jchs), but IBP's accessibility-specific revenue is not established and its packet hypothesis is 'Low.'
- Evidence
- No company-specific evidence was fetched; the theme link is weak and diluted, and any accessibility/retrofit revenue share is unquantified.
- Materiality
- not assessed — Diluted, indirect exposure with no fetched evidence of accessibility-specific materiality; more a housing-cycle than an aging-in-place play.
- Investability view
- Weak thematic fit; behaves as a new-construction/housing-cycle exposure rather than a targeted aging-in-place beneficiary.
Next diligence: Determine whether IBP has any accessibility/retrofit revenue; new-construction vs repair-and-remodel mix; regional housing exposure.
Home accessibility products (second-order) - water/kitchen and security brands (e.g., Moen) that include accessibility-relevant fixtures.Fortune Brands owns brands that supply bath/kitchen products relevant to accessible remodels supporting aging in place, and JCHS shows a large accessibility-need gap (fewer than one-third of homes have basic accessibility features; src-jchs). However, accessibility-specific SKUs are a small, unquantified slice of a broad home-products portfolio.
- Evidence
- No company financials or accessibility-revenue disclosure were fetched; the link is plausible but unquantified and diluted across the portfolio.
- Materiality
- not assessed — Plausible but unquantified and diluted exposure with no fetched company-specific evidence supporting financial materiality.
- Investability view
- Indirect beneficiary of the aging-remodel cycle rather than a pure thematic exposure; driven more by repair-and-remodel and housing-turnover trends.
Next diligence: Identify specific accessibility product lines and their revenue share; repair-and-remodel vs new-construction exposure; pricing power in accessibility SKUs.
Home-modification distribution (second-order) - home-improvement retailer serving DIY and Pro accessibility/remodel demand.Lowe's is a retail channel for accessibility and remodel products, and aging homeowners dominate remodeling spend (homeowners 55+ driving most decade gains; src-jchs). But aging-in-place is a small, unbroken-out part of Lowe's broad home-improvement revenue; a review of its newsroom found no dedicated aging-in-place disclosure.
- Evidence
- No aging-specific financials or program disclosures were fetched (newsroom review found none); exposure is incidental within a large general-retail base.
- Materiality
- not assessed — Highly diluted exposure with no fetched company evidence of material aging-in-place revenue.
- Investability view
- Primarily a macro home-improvement/housing-turnover play with only incidental aging-in-place exposure; not a targeted way to express the theme.
Next diligence: Any aging-in-place merchandising or Pro-services data; repair-and-remodel demand trends; share of sales from accessibility categories.